国家癌症研究所癌症治疗部的筛查项目的最新结果

Abraham Goldin , John M. Venditti , John S. Macdonald , Franco M. Muggia , Jane E. Henney , Vincent T. Devita Jr.
{"title":"国家癌症研究所癌症治疗部的筛查项目的最新结果","authors":"Abraham Goldin ,&nbsp;John M. Venditti ,&nbsp;John S. Macdonald ,&nbsp;Franco M. Muggia ,&nbsp;Jane E. Henney ,&nbsp;Vincent T. Devita Jr.","doi":"10.1016/0014-2964(81)90027-X","DOIUrl":null,"url":null,"abstract":"<div><p>The prospective screening program at the Division of Cancer Treatment, National Cancer Institute, has now been in operation for several years and is making steady progress in the identification of new synthetic compounds and natural products of potential interest for the clinic. Data are presented on four categories of drugs that have been tested in the new screening panel: (a) clinically established antitumor agents; (b) new drugs and drugs for which there is renewed clinical interest based on activity in the new screen and previously inadequate clinical trial; (c) drugs in the initial phases of clinical trial; (d) compounds in development. An analysis of the data is presented, taking into account a series of important questions that are being addressed prospectively to the new screen. Although the ability to provide definitive answers must await feedback from clinical testing of compounds recommended by the screen, some generalizations appear to be emerging, and these are discussed. A comparison is made of the activity of drugs in the treatment of human tumors growing in two sites, subcutaneously and under the renal capsule. The subrenal capsule model appears to be somewhat more sensitive to drugs than the subcutaneous model and may provide certain advantages for initial panel testing. Attention is drawn to the potential usefulness in a screening program of the newly developed clonogenic techniques for growing human tumors. The screening program at the Division of Cancer Treatment is viewed as a dynamic entity, subject to modification in accordance with acquired experience.</p></div>","PeriodicalId":100497,"journal":{"name":"European Journal of Cancer (1965)","volume":"17 2","pages":"Pages 129-142"},"PeriodicalIF":0.0000,"publicationDate":"1981-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0014-2964(81)90027-X","citationCount":"217","resultStr":"{\"title\":\"Current results of the screening program at the division of cancer treatment, national cancer institute\",\"authors\":\"Abraham Goldin ,&nbsp;John M. Venditti ,&nbsp;John S. Macdonald ,&nbsp;Franco M. Muggia ,&nbsp;Jane E. Henney ,&nbsp;Vincent T. Devita Jr.\",\"doi\":\"10.1016/0014-2964(81)90027-X\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The prospective screening program at the Division of Cancer Treatment, National Cancer Institute, has now been in operation for several years and is making steady progress in the identification of new synthetic compounds and natural products of potential interest for the clinic. Data are presented on four categories of drugs that have been tested in the new screening panel: (a) clinically established antitumor agents; (b) new drugs and drugs for which there is renewed clinical interest based on activity in the new screen and previously inadequate clinical trial; (c) drugs in the initial phases of clinical trial; (d) compounds in development. An analysis of the data is presented, taking into account a series of important questions that are being addressed prospectively to the new screen. Although the ability to provide definitive answers must await feedback from clinical testing of compounds recommended by the screen, some generalizations appear to be emerging, and these are discussed. A comparison is made of the activity of drugs in the treatment of human tumors growing in two sites, subcutaneously and under the renal capsule. The subrenal capsule model appears to be somewhat more sensitive to drugs than the subcutaneous model and may provide certain advantages for initial panel testing. Attention is drawn to the potential usefulness in a screening program of the newly developed clonogenic techniques for growing human tumors. The screening program at the Division of Cancer Treatment is viewed as a dynamic entity, subject to modification in accordance with acquired experience.</p></div>\",\"PeriodicalId\":100497,\"journal\":{\"name\":\"European Journal of Cancer (1965)\",\"volume\":\"17 2\",\"pages\":\"Pages 129-142\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0014-2964(81)90027-X\",\"citationCount\":\"217\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer (1965)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/001429648190027X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer (1965)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/001429648190027X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 217

摘要

美国国家癌症研究所癌症治疗部的前瞻性筛查项目已经运行了几年,在鉴定新的合成化合物和临床潜在兴趣的天然产物方面取得了稳步进展。数据介绍了在新的筛选小组中测试的四类药物:(a)临床建立的抗肿瘤药物;(b)新药和基于新筛选活动和先前不充分的临床试验而重新引起临床兴趣的药物;(c)处于临床试验初期的药物;(d)正在开发的化合物。提出了对数据的分析,考虑到新屏幕正在解决的一系列重要问题。虽然提供明确答案的能力必须等待筛选推荐的化合物的临床试验反馈,但一些概括似乎正在出现,并对其进行讨论。比较了药物治疗生长在皮下和肾包膜下两个部位的人类肿瘤的活性。与皮下模型相比,肾下胶囊模型似乎对药物更敏感,可能为初始面板试验提供某些优势。注意到潜在的有用性,在筛选程序的新开发的克隆技术生长的人类肿瘤。癌症治疗部门的筛查项目被视为一个动态的实体,可以根据获得的经验进行修改。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Current results of the screening program at the division of cancer treatment, national cancer institute

The prospective screening program at the Division of Cancer Treatment, National Cancer Institute, has now been in operation for several years and is making steady progress in the identification of new synthetic compounds and natural products of potential interest for the clinic. Data are presented on four categories of drugs that have been tested in the new screening panel: (a) clinically established antitumor agents; (b) new drugs and drugs for which there is renewed clinical interest based on activity in the new screen and previously inadequate clinical trial; (c) drugs in the initial phases of clinical trial; (d) compounds in development. An analysis of the data is presented, taking into account a series of important questions that are being addressed prospectively to the new screen. Although the ability to provide definitive answers must await feedback from clinical testing of compounds recommended by the screen, some generalizations appear to be emerging, and these are discussed. A comparison is made of the activity of drugs in the treatment of human tumors growing in two sites, subcutaneously and under the renal capsule. The subrenal capsule model appears to be somewhat more sensitive to drugs than the subcutaneous model and may provide certain advantages for initial panel testing. Attention is drawn to the potential usefulness in a screening program of the newly developed clonogenic techniques for growing human tumors. The screening program at the Division of Cancer Treatment is viewed as a dynamic entity, subject to modification in accordance with acquired experience.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信